Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Pediatric Solid Tumor: early-phase trial registry

5 of 11 indexed Pediatric Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 5 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Pediatric Solid Tumor: 11 US clinical trials tracked, 5 recruiting.

Pediatric Solid Tumor is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Seattle Children's Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition pediatric-solid-tumor

OPEN 5 | RECR 45% | LATE 0 | EARLY 8 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Breast Carcinoma (45% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Pediatric Solid Tumor (this)45%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Pediatric Solid Tumor

Pediatric Solid Tumor lists 5 open slots (45% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pediatric Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pediatric Solid Tumor recruits in line with its size-band peers.

    5 of 11 indexed trials (45.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Pediatric Solid Tumor research.

    Seattle Children's Hospital accounts for 2 of 11 trials (18.2%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Pediatric Solid Tumor trials plan to enrol fewer than 100 people.

    Median target enrolment is 64 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.

  4. Pediatric Solid Tumor research is mostly interventional.

    8 interventional and 3 observational studies make up this index (72.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18

Open and recent trials

11 total, page 1 of 1

RECRUITING 10,000 participants

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

National Cancer Institute (NCI)

NCT03739827

RECRUITING Phase 1 116 participants

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

National Cancer Institute (NCI)

NCT04222413

RECRUITING Phase 1 64 participants

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

St. Jude Children's Research Hospital

NCT05468359

RECRUITING Phase 1 32 participants

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research Hospital

NCT04897321

RECRUITING Phase 1 20 participants

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Washington University School of Medicine

NCT05521984

ACTIVE NOT RECRUITING 825 participants

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

Dana-Farber Cancer Institute

NCT02520713

ACTIVE NOT RECRUITING Phase 1 68 participants

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

NCT04483778

ACTIVE NOT RECRUITING Phase 1 44 participants

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

NCT03618381

ACTIVE NOT RECRUITING Phase 1 30 participants

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Cellectar Biosciences

NCT03478462

COMPLETED 101 participants

iCAT for Recurrent/Refractory/HR Solid Tumors

Dana-Farber Cancer Institute

NCT01853345

COMPLETED Phase 1 29 participants

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Eli Lilly and Company

NCT02564198

Phase Distribution

PhaseTrial count
Phase 1 8

Named interventions

Most-linked intervention names on Pediatric Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
3 trials
second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG Biological
1 trials
second generation 4-1BBζ EGFR806-EGFRt Biological
1 trials
Genetic testing and GAIN report Genetic
1 trials
CLR 131 Drug
1 trials
second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG Biological
1 trials
second generation 4-1BBζ B7H3-EGFRt-DHFR Biological
1 trials
Metarrestin Drug
1 trials

US sites by state

Facility locations filed on Pediatric Solid Tumor trials. A trial with sites in several states counts in each.

Washington 4 trials
Texas 4 trials
New York 4 trials
California 4 trials
Tennessee 3 trials
Ohio 3 trials
Maryland 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pediatric Solid Tumor page

11 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pediatric Solid Tumor condition card totals 11 registered trials; most-linked intervention Cyclophosphamide; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.